Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer

Huiming Chen; Shijuan Gao; Jiandong Li; Dong Liu; Chunjie Sheng; Chen Yao; Wei Jiang; Jiaoxiang Wu; Shuai Chen; Wenlin Huang

doi:10.18632/oncotarget.3790

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer

Huiming Chen, Shijuan Gao, Jiandong Li, Dong Liu, Chunjie Sheng, Chen Yao, Wei Jiang, Jiaoxiang Wu, Shuai Chen and Wenlin Huang _

PDF | HTML | How to cite

Oncotarget. 2015; 6:13049-13059. https://doi.org/10.18632/oncotarget.3790

Metrics: PDF 2602 views | HTML 2682 views | ?

Abstract

Huiming Chen1,2, Shijuan Gao1, Jiandong Li1, Dong Liu1, Chunjie Sheng1, Chen Yao1,2, Wei Jiang1, Jiaoxiang Wu1,2, Shuai Chen1,3 and Wenlin Huang1,3,4

1 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

2 School of Life Sciences, Anhui University, Hefei 230039, China

3 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

4 The Key Laboratory of Tumor Targeted Medicine in Guangdong Province, Guangzhou Double Bio-product Inc., Guangzhou 510663, China

Correspondence to:

Wenlin Huang, email:

Shuai Chen, email:

Keywords: epigenetic cancer therapy, surface plasmon resonance, cell cycle, apoptosis, cell migration

Received: December 18, 2014 Accepted: March 18, 2015 Published: April 12, 2015

Abstract

Polycomb repressive complex 2 (PRC2), which is responsible for the trimethylation of H3K27 (H3K27me3), plays a part in tumorigenesis, development and/or maintenance of adult tissue specificity. The pivotal role of PRC2 in cancer makes it a therapeutic target for epigenetic cancer therapy. However, natural compounds targeting the enhancer of zeste homolog 2 (EZH2) - embryonic ectoderm development (EED) interaction to disable PRC2 complex are scarcely reported. Here, we reported the screening and identification of natural compounds which could disrupt the EZH2-EED interaction. One of these compounds, wedelolactone, binds to EED with a high affinity (KD = 2.82 μM), blocks the EZH2-EED interaction in vitro, induces the degradation of PRC2 core components and modulates the expression of detected PRC2 downstream targets and cancer-related genes. Furthermore, some PRC2-dependent cancer cells undergone growth arrest upon treatment with wedelolactone. Thus, wedelolactone and its derivatives which target the EZH2-EED interaction could be candidates for the treatment of PRC2-dependent cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3790

Publication Alerts

Research Papers:

Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer

Abstract